NCT02452528View on ClinicalTrials.gov

Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus

PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Chronic Hepatitis B
Interventions
DRUG

ARC-520

DRUG

Placebo

DRUG

Entecavir

0.5 or 1.0 mg/day orally

DRUG

Tenofovir

300 mg/day orally

DRUG

diphenhydramine

50 mg orally as pretreatment antihistamine

Trial Locations (4)

10029

Ichan School of Medicine at Mount Sinai, New York

33136

Univ. Of Miami School Of Medicine/Center For Liver Diseases, Miami

78215

The Texas Liver Institute, San Antonio

94118

Kaiser Permanente, San Francisco

Sponsors
All Listed Sponsors
lead

Arrowhead Pharmaceuticals

INDUSTRY